BMJ 305 : 14241429 Sachdev D, Li SL, Hartell JS, Fujita-Yamaguchi Y, Miller JS, Yee D (2003) A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist with a prolonged half-life of approximately 7 days [1] , approved for chronic weight management and glycemic control
Nutritional solutions are increasingly required to mitigate side effects such as muscle loss, which affects over 40% of GLP-1 users
Maiese K, Chong ZZ, Shang YC, Hou J: Clever cancer strategies with FoxO transcription factors
Pediatric Although there is no specific information comparing use of levocarnitine in children with use in other age groups, this dietary supplement is not expected to cause different side effects or problems in children than it does in adults